Celgene resubmits NDA for MS candidate ozanimod

Celgene said it resubmitted an NDA to FDA for ozanimod to treat relapsing forms of multiple sclerosis. The company submitted earlier this month

Read the full 232 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE